{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:06:27Z","timestamp":1793815587590,"version":"4.6.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["72204039"],"award-info":[{"award-number":["72204039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["72204039"],"award-info":[{"award-number":["72204039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["72204039"],"award-info":[{"award-number":["72204039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["72204039"],"award-info":[{"award-number":["72204039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["72204039"],"award-info":[{"award-number":["72204039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["72204039"],"award-info":[{"award-number":["72204039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["72204039"],"award-info":[{"award-number":["72204039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Sichuan Province","award":["2023NSFSC1045"],"award-info":[{"award-number":["2023NSFSC1045"]}]},{"name":"the Natural Science Foundation of Sichuan Province","award":["2023NSFSC1045"],"award-info":[{"award-number":["2023NSFSC1045"]}]},{"name":"the Natural Science Foundation of Sichuan Province","award":["2023NSFSC1045"],"award-info":[{"award-number":["2023NSFSC1045"]}]},{"name":"the Natural Science Foundation of Sichuan Province","award":["2023NSFSC1045"],"award-info":[{"award-number":["2023NSFSC1045"]}]},{"name":"the Natural Science Foundation of Sichuan Province","award":["2023NSFSC1045"],"award-info":[{"award-number":["2023NSFSC1045"]}]},{"name":"the Natural Science Foundation of Sichuan Province","award":["2023NSFSC1045"],"award-info":[{"award-number":["2023NSFSC1045"]}]},{"name":"the Natural Science Foundation of Sichuan Province","award":["2023NSFSC1045"],"award-info":[{"award-number":["2023NSFSC1045"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13726-8","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T13:41:01Z","timestamp":1740750061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Is ADC a rising star in solid tumor? An umbrella review of systematic reviews and meta-analyses"],"prefix":"10.1186","volume":"25","author":[{"given":"Hua","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"issue":"4","key":"13726_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.bpa.2013.10.010","volume":"27","author":"K Popat","year":"2013","unstructured":"Popat K, McQueen K, Feeley TW. The global burden of cancer. Best Pract Res Clin Anaesthesiol. 2013;27(4):399\u2013408. https:\/\/doi.org\/10.1016\/j.bpa.2013.10.010.","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"13726_CR2","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMra1204479","volume":"366","author":"VT DeVita","year":"2012","unstructured":"DeVita VT, Rosenberg SA. Two hundred years of cancer research. N Engl J Med. 2012;366:2207\u201314.","journal-title":"N Engl J Med"},{"issue":"10","key":"13726_CR3","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.3390\/cancers14102429","volume":"14","author":"A Di Federico","year":"2022","unstructured":"Di Federico A, Mosca M, Pagani R, et al. Immunotherapy in Pancreatic Cancer: why do we keep Failing? A focus on Tumor Immune Microenvironment, predictive biomarkers and treatment outcomes. Cancers (Basel). 2022;14(10):2429. https:\/\/doi.org\/10.3390\/cancers14102429. Published 2022 May 14.","journal-title":"Cancers (Basel)"},{"key":"13726_CR4","doi-asserted-by":"publisher","unstructured":"Guven DC, Erul E, Kaygusuz Y, et al. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support Care Cancer. 2023;31(12):624. https:\/\/doi.org\/10.1007\/s00520-023-08083-w. Published 2023 Oct 11.","DOI":"10.1007\/s00520-023-08083-w"},{"key":"13726_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc2394","volume":"8","author":"K Strebhardt","year":"2008","unstructured":"Strebhardt K, Ullrich A. Paul Ehrlich\u2019s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8:473\u201380.","journal-title":"Nat Rev Cancer"},{"key":"13726_CR6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody\u2013drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327\u201344.","journal-title":"Nat Rev Clin Oncol"},{"key":"13726_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corvaoa N. Strategies and challenges for the next generation of antibody\u2013drug conjugates. Nat Rev Drug Discov. 2017;16:315\u201337.","journal-title":"Nat Rev Drug Discov"},{"key":"13726_CR8","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1158\/1078-0432.CCR-14-0012","volume":"20","author":"L Amiri-Kordestani","year":"2014","unstructured":"Amiri-Kordestani L, Blumenthal GM, Xu QC, et al. FDA approval: ado trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014;20:4436\u201341.","journal-title":"Clin Cancer Res"},{"key":"13726_CR9","doi-asserted-by":"publisher","unstructured":"Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer [published correction appears in N Engl J Med. 2013;368(25):2442]. N Engl J Med. 2012;367(19):1783\u20131791. https:\/\/doi.org\/10.1056\/NEJMoa1209124","DOI":"10.1056\/NEJMoa1209124"},{"issue":"12","key":"13726_CR10","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for breast Cancer. N Engl J Med. 2022;386(12):1143\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2115022.","journal-title":"N Engl J Med"},{"issue":"29","key":"13726_CR11","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","volume":"37","author":"JE Rosenberg","year":"2019","unstructured":"Rosenberg JE, O\u2019Donnell PH, Balar AV, et al. Pivotal trial of Enfortumab Vedotin in Urothelial Carcinoma after Platinum and Anti-programmed Death 1\/Programmed death Ligand 1 therapy. J Clin Oncol. 2019;37(29):2592\u2013600. https:\/\/doi.org\/10.1200\/JCO.19.01140.","journal-title":"J Clin Oncol"},{"key":"13726_CR12","doi-asserted-by":"crossref","unstructured":"Rugo HS, Bardia A, Marme F et al. Sacituzumabgovitecan in hormone receptor-positive\/human epidermalgrowth factor receptor 2-negative metastatic breast cancer[J]. J Clin Oncol, 2022;40(29):3365\u201376.","DOI":"10.1200\/JCO.22.01002"},{"key":"13726_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00529","author":"N Turner","year":"2024","unstructured":"Turner N, Saura C, Aftimos P, et al. Trastuzumab Duocarmazine in Pretreated human epidermal growth factor receptor 2-Positive Advanced or metastatic breast Cancer: an Open-Label, Randomized, Phase III Trial (TULIP). J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.24.00529.","journal-title":"J Clin Oncol"},{"key":"13726_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","volume":"32","author":"KN Moore","year":"2021","unstructured":"Moore KN, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32:757\u201365.","journal-title":"Ann Oncol"},{"key":"13726_CR15","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. https:\/\/doi.org\/10.1136\/bmj.j4008.","journal-title":"BMJ"},{"key":"13726_CR16","unstructured":"Chap. 5.2.4.2 Imprecision in in systematic reviews in Sch\u00fcnemann H BJ, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from http:\/\/guidelinedevelopment.org\/handbook. Accessed Dec 2024."},{"issue":"20","key":"13726_CR17","first-page":"2540","volume":"34","author":"XU Yinxue","year":"2023","unstructured":"Yinxue XU, Lei Zhang, Xiwen Qiao, et al. Efficacy and safety of antibody-drug conjugates in the treatment of breast cancer: a meta-analysis. China Pharm. 2023;34(20):2540\u20134.","journal-title":"China Pharm"},{"key":"13726_CR18","unstructured":"Ting LIU, Lei CHEN, Li YU. Meta analysis of TDMl efficacy and drug safety in patientswith HER2 positive breast cancer. Chin J Cancer Prev Treat, 202l;28(17):1345\u201354."},{"issue":"8","key":"13726_CR19","first-page":"3266","volume":"13","author":"ZL Cai","year":"2023","unstructured":"Cai ZL, Yang HT, Huang T, et al. Efficacy and safety of trastuzumab deruxtecan in patients with solid tumors: a systematic review and meta-analysis of 3 randomized controlled trials. Am J Cancer Res. 2023;13(8):3266\u201374.","journal-title":"Am J Cancer Res"},{"key":"13726_CR20","doi-asserted-by":"publisher","first-page":"204209862091505","DOI":"10.1177\/2042098620915058","volume":"11","author":"AM Cobert","year":"2020","unstructured":"Cobert AM, Helms C, Larck C, et al. Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis. Ther Adv Drug Saf. 2020;11:2042098620915058. https:\/\/doi.org\/10.1177\/2042098620915058.","journal-title":"Ther Adv Drug Saf"},{"key":"13726_CR21","unstructured":"Yan Bing-xue, Huang Shi-fen, Xia Yun-xia, et al. A Meta-analysis of the efficacy and safety of T-DMl contained regime for neoadjuvant treatment inHER-2 positive breast cancer. Journal of Lanzhou University (Medical Sciences). 2021;47(3):1\u20137."},{"key":"13726_CR22","doi-asserted-by":"publisher","first-page":"103758","DOI":"10.1016\/j.critrevonc.2022.103758","volume":"177","author":"L Zhang","year":"2022","unstructured":"Zhang L, Shen D, Yu L, et al. Is antibody-drug conjugate a rising star for clinical treatment of solid tumors? A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022;177:103758. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103758.","journal-title":"Crit Rev Oncol Hematol"},{"key":"13726_CR23","unstructured":"Danni YANG, Jia YU, Jinghua RUAN et al. Advanced Breast Cancer Systematic Review on \u2018Trastuzumab Emtansine for Injection in the Treatment of HER-2-Positive. Evaluation and analysis of drug-use in hospitals of China. 2023;23(3):346\u201351."},{"issue":"60","key":"13726_CR24","doi-asserted-by":"publisher","first-page":"102458","DOI":"10.18632\/oncotarget.22270","volume":"8","author":"H Yan","year":"2017","unstructured":"Yan H, Yu K, Zhang K, Liu L, Li Y. Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial. Oncotarget. 2017;8(60):102458\u201367. https:\/\/doi.org\/10.18632\/oncotarget.22270.","journal-title":"Oncotarget"},{"key":"13726_CR25","doi-asserted-by":"publisher","first-page":"104305","DOI":"10.1016\/j.critrevonc.2024.104305","volume":"196","author":"R Ma","year":"2024","unstructured":"Ma R, Shi Y, Yan R, Yin S, Bu H, Huang J. Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low\/positive advanced breast cancer:a meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2024;196:104305. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104305.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"14","key":"13726_CR26","first-page":"2447","volume":"29","author":"YAN Bingxue","year":"2021","unstructured":"Bingxue YAN, Shifen HUANG, Yunxia XA, et al. The Meta - analysis of the efficacy and safety of trastuzumab-emtansine (T-DMl) in the treatment of HER-2 positive advanced breast cancer. Mod Oncol. 2021;29(14):2447\u201353.","journal-title":"Mod Oncol"},{"key":"13726_CR27","unstructured":"Hong XUE, Peng YUE, Jing-Jing LIU et al. Efficacy and safety of Tratuzumab-Emtansine (T-DMl) in treatment of her-2-positive Advanced or metastatic breast Cancer: a Meta-analysis. ChinaCancer 2018;27(9):726\u201332."},{"issue":"5","key":"13726_CR28","doi-asserted-by":"publisher","first-page":"e15282","DOI":"10.7759\/cureus.15282","volume":"13","author":"N Jahan","year":"2021","unstructured":"Jahan N, Rehman S, Khan R, et al. Relative risk of Peripheral Neuropathy with ado-trastuzumab emtansine (T-DM1) compared to taxane-based regimens in human epidermal growth factor receptor 2 (HER2)-Positive cancers: a systematic review and Meta-analysis. Cureus. 2021;13(5):e15282. https:\/\/doi.org\/10.7759\/cureus.15282. Published 2021 May 27.","journal-title":"Cureus"},{"issue":"4","key":"13726_CR29","first-page":"247","volume":"39","author":"GUO Yi-meng","year":"2020","unstructured":"Yi-meng GUO, Jing YANG, Hong-xia YAN, et al. Efficacy and safety of tratuzumab-emtansine in treatment of HER-2 positive breast cancer: a systematic review. Chin J New Drugs Clin Rem. 2020;39(4):247\u201352.","journal-title":"Chin J New Drugs Clin Rem"},{"issue":"11","key":"13726_CR30","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1080\/17512433.2022.2121704","volume":"15","author":"K Liu","year":"2022","unstructured":"Liu K, Li YH, Zhang X, et al. Incidence and risk of severe adverse events associated with trastuzumab emtansine (T-DM1) in the treatment of breast cancer: an up-to-date systematic review and meta-analysis of randomized controlled clinical trials. Expert Rev Clin Pharmacol. 2022;15(11):1343\u201350. https:\/\/doi.org\/10.1080\/17512433.2022.2121704.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"13726_CR31","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.4103\/jcrt.jcrt_1095_21","volume":"18","author":"Y Yeh","year":"2022","unstructured":"Yeh Y, Chen C, Ko Y. Effectiveness and cost-effectiveness of trastuzumab emtansine in women with HER2-positive locally advanced or metastatic breast cancer: a systematic review and meta-analysis. J Cancer Res Ther. 2022;18(4):1061\u201372. https:\/\/doi.org\/10.4103\/jcrt.jcrt_1095_21.","journal-title":"J Cancer Res Ther"},{"issue":"5","key":"13726_CR32","first-page":"539","volume":"33","author":"ZHANG Xiaoging","year":"2024","unstructured":"Xiaoging ZHANG, Shuai LIU, Kai ZHANG, et al. Efficacy and safety of trastuzumab deruxtecan in the treatment of breast cancer: a Meta-analysis. Chin J Pharmacoepidemiol. 2024;33(5):539\u201347.","journal-title":"Chin J Pharmacoepidemiol"},{"issue":"12","key":"13726_CR33","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in previously treated Advanced Urothelial Carcinoma. N Engl J Med. 2021;384(12):1125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2035807.","journal-title":"N Engl J Med"},{"issue":"16","key":"13726_CR34","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A BARDIA","year":"2021","unstructured":"Bardia A, Hurvitz S A, Tolaney S M, et al. Saci-tuzumab govitecan in metastatic triple-negative breast can-cer[J]. N Engl JMed. 2021;384(16):1529\u201341.","journal-title":"N Engl JMed"},{"issue":"10411","key":"13726_CR35","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10411):1423\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(23)01245-X.","journal-title":"Lancet"},{"issue":"24","key":"13726_CR36","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1200\/JCO.24.00733","volume":"42","author":"LG Paz-Ares","year":"2024","unstructured":"Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab Govitecan Versus Docetaxel for previously treated Advanced or Metastatic Non-small Cell Lung Cancer: the randomized, open-label phase III EVOKE-01 study. J Clin Oncol. 2024;42(24):2860\u201372. https:\/\/doi.org\/10.1200\/JCO.24.00733.","journal-title":"J Clin Oncol"},{"key":"13726_CR37","doi-asserted-by":"publisher","unstructured":"Thuss-Patience PC, Shah MA, Ohtsu A et al. Trastuzumab emtansine versus taxane use for previouslytreated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junctionadenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study. LancetOncol.2017,18:640\u2013\u200953. https:\/\/doi.org\/10.1016\/S1470-2045(17)30111-0","DOI":"10.1016\/S1470-2045(17)30111-0"},{"issue":"1","key":"13726_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","volume":"391","author":"I Vergote","year":"2024","unstructured":"Vergote I, Gonz\u00e1lez-Mart\u00edn A, Fujiwara K, et al. Tisotumab Vedotin as Second- or third-line therapy for recurrent cervical Cancer. N Engl J Med. 2024;391(1):44\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2313811.","journal-title":"N Engl J Med"},{"issue":"3","key":"13726_CR39","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/onco.13628","volume":"26","author":"C Kollmannsberger","year":"2021","unstructured":"Kollmannsberger C, Choueiri TK, Heng DYC, et al. A randomized phase II study of AGS-16C3F Versus Axitinib in previously treated patients with metastatic renal cell carcinoma. Oncologist. 2021;26(3):182\u2013e361. https:\/\/doi.org\/10.1002\/onco.13628.","journal-title":"Oncologist"},{"issue":"4","key":"13726_CR40","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","volume":"23","author":"HL Kindler","year":"2022","unstructured":"Kindler HL, Novello S, Bearz A, et al. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol. 2022;23(4):540\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(22)00061-4.","journal-title":"Lancet Oncol"},{"key":"13726_CR41","doi-asserted-by":"publisher","first-page":"107928","DOI":"10.1016\/j.lungcan.2024.107928","volume":"195","author":"AS Mansfield","year":"2024","unstructured":"Mansfield AS, Vivien Yin J, Bradbury P, et al. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. Lung Cancer. 2024;195:107928. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107928.","journal-title":"Lung Cancer"},{"issue":"4","key":"13726_CR42","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/annonc\/mdy023","volume":"29","author":"S Banerjee","year":"2018","unstructured":"Banerjee S, Oza AM, Birrer MJ, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018;29(4):917\u201323. https:\/\/doi.org\/10.1093\/annonc\/mdy023.","journal-title":"Ann Oncol"},{"key":"13726_CR43","doi-asserted-by":"publisher","first-page":"104230","DOI":"10.1016\/j.critrevonc.2023.104230","volume":"194","author":"Y Wang","year":"2024","unstructured":"Wang Y, Liu L, Jin X, Yu Y. Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2024;194:104230. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104230.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"13726_CR44","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1111\/jog.16126","volume":"50","author":"ME Mokresh","year":"2024","unstructured":"Mokresh ME, Alomari O, Varda A, et al. Safety and efficacy of tisotumab vedotin with cervical cancers: a systematic review and meta-analysis. J OBSTET GYNAECOL RE. 2024;50(12):2195\u2013210. https:\/\/doi.org\/10.1111\/jog.16126.","journal-title":"J OBSTET GYNAECOL RE"},{"issue":"2","key":"13726_CR45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72(2):165\u201382. https:\/\/doi.org\/10.3322\/caac.21705.","journal-title":"CA Cancer J Clin"},{"key":"13726_CR46","doi-asserted-by":"publisher","first-page":"101795","DOI":"10.1016\/j.eclinm.2022.101795","volume":"55","author":"Z Fu","year":"2022","unstructured":"Fu Z, Liu J, Li S, Shi C, Zhang Y. Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. E Clin Med. 2022;55:101795. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101795.","journal-title":"E Clin Med"},{"key":"13726_CR47","doi-asserted-by":"publisher","first-page":"103960","DOI":"10.1016\/j.critrevonc.2023.103960","volume":"184","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, Shen G, Li J, et al. Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2023;184:103960. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103960.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"13726_CR48","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315\u201337. https:\/\/doi.org\/10.1038\/nrd.2016.268.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"13726_CR49","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s00280-011-1817-3","volume":"69","author":"S Girish","year":"2012","unstructured":"Girish S, Gupta M, Wang B, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol. 2012;69(5):1229\u201340. https:\/\/doi.org\/10.1007\/s00280-011-1817-3.","journal-title":"Cancer Chemother Pharmacol"},{"key":"13726_CR50","doi-asserted-by":"publisher","first-page":"967017","DOI":"10.3389\/fphar.2022.967017","volume":"13","author":"S Xia","year":"2022","unstructured":"Xia S, Zhao YC, Guo L, et al. Do antibody-drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study. Front Pharmacol. 2022;13:967017. https:\/\/doi.org\/10.3389\/fphar.2022.967017.","journal-title":"Front Pharmacol"},{"issue":"1","key":"13726_CR51","doi-asserted-by":"publisher","first-page":"21386","DOI":"10.1038\/s41598-024-71977-0","volume":"14","author":"Y Chen","year":"2024","unstructured":"Chen Y, Ren X, Dai Y, Wang Y. Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system. Sci Rep. 2024;14(1):21386. https:\/\/doi.org\/10.1038\/s41598-024-71977-0.","journal-title":"Sci Rep"},{"key":"13726_CR52","doi-asserted-by":"publisher","first-page":"1378010","DOI":"10.3389\/fphar.2024.1378010","volume":"15","author":"P Long","year":"2024","unstructured":"Long P, Li S, Pan L, Wang Y, Chen W, Wang X. Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database. Front Pharmacol. 2024;15:1378010. https:\/\/doi.org\/10.3389\/fphar.2024.1378010.","journal-title":"Front Pharmacol"},{"issue":"3","key":"13726_CR53","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21(3):203\u201323. https:\/\/doi.org\/10.1038\/s41571-023-00850-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"13726_CR54","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/ph13090245","volume":"13","author":"N Joubert","year":"2020","unstructured":"Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Antibody-drug conjugates: the last decade. Pharmaceuticals (Basel). 2020;13(9):245. https:\/\/doi.org\/10.3390\/ph13090245. Published 2020 Sep 14.","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13726-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13726-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13726-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T13:41:09Z","timestamp":1740750069000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13726-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13726"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13726-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. All the data involved in this study were extracted from published articles.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"380"}}